World's Best Scientists 2026 revealed!
Hans Wildiers

Hans Wildiers

D-Index & Metrics

Medicine

D-Index
84
Citations
32196
World Ranking
14925
National Ranking
188

Hans Wildiers publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hans Wildiers sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 900 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hans Wildiers D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hans Wildiers sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hans Wildiers is affiliated with KU Leuven in Belgium and has a significant body of research primarily in the fields of medicine, biochemistry, genetics, and molecular biology. Their academic work spans multiple subfields, including oncology, pulmonary and respiratory medicine, cancer research, radiology and nuclear medicine, and genetics.

The research focus covers diverse topics such as advanced breast cancer therapies, breast cancer treatment studies, cancer treatment and pharmacology, HER2/EGFR in cancer research, frailty in older adults, cancer immunotherapy and biomarkers, and cancer genomics and diagnostics.

Frequent coauthors in Hans Wildiers' scientific collaborations include:

  • Patrick Neven
  • Kevin Punie
  • Giuseppe Floris
  • Ann Smeets
  • Christine Desmedt

Hans Wildiers has published extensively in several scientific venues, with a large number of contributions appearing in:

  • Cancer Research
  • Annals of Oncology
  • Journal of Geriatric Oncology
  • Journal of Clinical Oncology
  • ESMO Open

Among recent papers, notable publications include:

  • "A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer" (2021, Nature Medicine)
  • "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial" (2020, Journal of Clinical Oncology)
  • "Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial" (2020, The Lancet Oncology)
  • "Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)" (2021, The Lancet Oncology)
  • "Cancer and Aging: Two Tightly Interconnected Biological Processes" (2021, Cancers)

Best Publications

  • Vascular Endothelial Growth Factor and Angiogenesis

    Ann Hoeben;Bart Landuyt;Martin S. Highley;Hans Wildiers

  • International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer

    Hans Wildiers;Pieter Heeren;Martine Puts;Eva Topinkova

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

    Xiaohong R. Yang;Jenny Chang-Claude;Ellen L. Goode;Fergus J. Couch

  • Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations

    L Decoster;K Van Puyvelde;S Mohile;U Wedding

  • Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio González-Martín;Patricia M LoRusso

  • Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

    Laura Biganzoli;Hans Wildiers;Catherine Oakman;Lorenza Marotti

  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

    Kyriaki Michailidou;Jonathan Beesley;Sara Lindstrom;Sander Canisius

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

    Nasim Mavaddat;Paul D.P. Pharoah;Kyriaki Michailidou;Jonathan Tyrer

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Maura N. Dickler;Sara Tolaney;Hope S. Rugo;Javier Cortés

  • Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio Gonzalez Martin;Patricia M LoRusso

  • A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

    Ayse Bassez;Hanne Vos;Laurien Van Dyck;Giuseppe Floris

  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial

    Cristina Saura;Mafalda Oliveira;Yin-Hsun Feng;Ming-Shen Dai

  • Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study.

    Pace participants;R A Audisio;D Pope;H S J Ramesh

  • Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    Sara A. Hurvitz;Miguel Martin;W. Fraser Symmans;Kyung Hae Jung

  • Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology

    Hans Wildiers;Ian Kunkler;Laura Biganzoli;Jacques Fracheboud

  • Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

    H Wildiers;G Guetens;G De Boeck;E Verbeken

  • Performance of Two Geriatric Screening Tools in Older Patients With Cancer

    Cindy Kenis;Lore Decoster;Katrien Van Puyvelde;Jacques De Grève

Frequent Co-Authors

Patrick Neven
Patrick Neven KU Leuven
Graham G. Giles
Graham G. Giles University of Melbourne
Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Hiltrud Brauch
Hiltrud Brauch German Cancer Research Center
Vessela N. Kristensen
Vessela N. Kristensen Oslo University Hospital
Roger L. Milne
Roger L. Milne Cancer Council Victoria
Jenny Chang-Claude
Jenny Chang-Claude German Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine in the USA opens up a variety of online degree options and progressive career pathways. For registered nurses aiming to become nurse practitioners, flexible adn to np bridge programs are designed to help you advance while balancing work commitments.

Those interested in preventive health and dietary wellness can explore online nutrition degrees, which provide specialized knowledge in food sciences and nutrition without the need for traditional on-campus study.

For those seeking leadership roles in healthcare, enrolling in top cahme accredited mha programs offers advanced training in healthcare administration and management—ideal for future hospital and healthcare system executives.

Nurses looking for academic advancement with flexible requirements may consider rn to bsn no clinical hours programs, which allow for degree completion online without additional in-person clinicals.

These online pathways make it easier for individuals at all stages of their medical careers to grow, specialize, and contribute to the evolving world of healthcare.

Best Scientists Citing Hans Wildiers

Trending Scientists

Recently Published Articles